Saturday 17 October 2026
Export EVGN’s income statement to Excel — free account
Evogene Ltd.
EVGN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.39
0.01
−2.50%
Follow EVGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (100.03%) | (115.46%) | (63.29%) | (18.64%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
2 | 3 | 4 | 3 | |
| (38.31%) | (45.04%) | (28.33%) | (8.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (605.29%) | |
Return on Tangible Assets |
(109.23%) | (113.85%) | (65.27%) | (15.31%) | |
Average Days of Receivables |
310.59 | 336.89 | 178.28 | 326.06 | |
Free Cash Flow per Share |
(0.88) | (1.15) | (1.72) | (1.81) | |
Free Cash Flow |
(10.78) | (11.19) | (13.56) | (15.80) | |
Capital Expenditures |
0.17 | 0.09 | (0.06) | (0.42) | |
| Other line items | |||||
Cash ROIC |
(71.31%) | (53.09%) | (54.32%) | (47.57%) | |
Accounts Receivable Turnover |
1.04 | 0.74 | 1.53 | 0.75 | |
Accounts Payable Turnover |
5.84 | 5.13 | 4.39 | 3.02 | |
Inventory Turnover |
2.71 | 2.33 | 4.04 | 1.40 | |
Average Days of Payables |
51.79 | 62.43 | 56.97 | 66.67 | |
Days of Inventory on Hand |
12.22 | 23.60 | 18.72 | 307.96 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
426.25% | 399.24% | 207.47% | 315.64% | |
Selling, General and Administrative Expense of Revenue |
338.26% | 310.95% | 149.55% | 242.54% | |
Share Based Compensation of Revenue |
18.23% | 22.07% | 16.97% | 34.16% | |
Interest Coverage |
(2.85) | (2.64) | (7.26) | (7.43) | |
Operating CF/Net income |
1.21 | 0.96 | 1.59 | 5.60 | |
Depreciation/Fixed assets |
6.75 | 5.09 | 3.04 | 2.21 | |
Capex/Depreciation |
0.05 | 0.02 | (0.02) | (0.16) | |
Revenue per Share |
0.14 | 0.19 | 0.49 | 0.26 | |
Operating CF per Share |
(0.90) | (1.16) | (1.71) | (1.76) | |
Capex per Share |
0.01 | 0.01 | (0.01) | (0.05) | |
Capex to Sales |
(0.10) | (0.05) | 0.01 | 0.19 |
Columns are period end dates